Skip to main content
Top
Published in: Cost Effectiveness and Resource Allocation 1/2007

Open Access 01-12-2007 | Methodology

The Quit Benefits Model: a Markov model for assessing the health benefits and health care cost savings of quitting smoking

Authors: Susan F Hurley, Jane P Matthews

Published in: Cost Effectiveness and Resource Allocation | Issue 1/2007

Login to get access

Abstract

Background

In response to the lack of comprehensive information about the health and economic benefits of quitting smoking for Australians, we developed the Quit Benefits Model (QBM).

Methods

The QBM is a Markov model, programmed in TreeAge, that assesses the consequences of quitting in terms of cases avoided of the four most common smoking-associated diseases, deaths avoided, and quality-adjusted life-years (QALYs) and health care costs saved (in Australian dollars, A$). Quitting outcomes can be assessed for males and females in 14 five year age-groups from 15–19 to 80–84 years.
Exponential models, based on data from large case-control and cohort studies, were developed to estimate the decline over time after quitting in the risk of acute myocardial infarction (AMI), stroke, lung cancer, chronic obstructive pulmonary disease (COPD), and death. Australian data for the year 2001 were sourced for disease incidence and mortality and health care costs. Utility of life estimates were sourced from an international registry and a meta analysis.
In this paper, outcomes are reported for simulated subjects followed up for ten years after quitting smoking. Life-years, QALYs and costs were estimated with 0%, 3% and 5% per annum discount rates. Summary results are presented for a group of 1,000 simulated quitters chosen at random from the Australian population of smokers aged between 15 and 74.

Results

For every 1,000 males chosen at random from the reference population who quit smoking, there is a an average saving in the first ten years following quitting of A$408,000 in health care costs associated with AMI, COPD, lung cancer and stroke, and a corresponding saving of A$328,000 for every 1,000 female quitters. The average saving per 1,000 random quitters is A$373,000. Overall 40 of these quitters will be spared a diagnosis of AMI, COPD, lung cancer and stroke in the first ten years following quitting, with an estimated saving of 47 life-years and 75 QALYs. Sensitivity analyses indicated that QBM predictions were robust to variations of ± 10% in parameter estimates.

Conclusion

The QBM can answer many of the questions posed by Australian policy-makers and health program funders about the benefits of quitting, and is a useful tool to evaluate tobacco control programs. It can easily be re-programmed with updated information or a set of epidemiologic data from another country.
Appendix
Available only for authorised users
Literature
1.
go back to reference White V, Hill D, Siahpush M, Bobevski I: How has the prevalence of cigarette smoking changed among Australian adults? Trends in smoking prevalence between 1980 and 2001. Tob Control 2003, 12 (Suppl II): ii67-ii74. White V, Hill D, Siahpush M, Bobevski I: How has the prevalence of cigarette smoking changed among Australian adults? Trends in smoking prevalence between 1980 and 2001. Tob Control 2003, 12 (Suppl II): ii67-ii74.
2.
go back to reference Tobacco Control: A Blue Chip Investment in Public Health. Melbourne, VicHealth Centre for Tobacco Control, The Cancer Council Victoria; 2003. Tobacco Control: A Blue Chip Investment in Public Health. Melbourne, VicHealth Centre for Tobacco Control, The Cancer Council Victoria; 2003.
3.
go back to reference Hurley SF, Scollo MM, Younie SJ, English DR, Swanson MG: The potential for tobacco control to reduce PBS costs for smoking-related cardiovascular disease. Medical Journal of Australia 2004, 181: 252–255.PubMed Hurley SF, Scollo MM, Younie SJ, English DR, Swanson MG: The potential for tobacco control to reduce PBS costs for smoking-related cardiovascular disease. Medical Journal of Australia 2004, 181: 252–255.PubMed
4.
go back to reference Hurley SF: The short-term impact of smoking cessation on myocardial infarction and stroke hospitalisations and costs in Australia. Medical Journal of Australia 2005, 183: 13–17.PubMed Hurley SF: The short-term impact of smoking cessation on myocardial infarction and stroke hospitalisations and costs in Australia. Medical Journal of Australia 2005, 183: 13–17.PubMed
5.
go back to reference Tengs TO, Osgood ND, Chen LL: The cost-effectiveness of intensive national school-based anti-tobacco education: results from the tobacco policy model. Prev Med 2001, 33: 558–570. 10.1006/pmed.2001.0922PubMedCrossRef Tengs TO, Osgood ND, Chen LL: The cost-effectiveness of intensive national school-based anti-tobacco education: results from the tobacco policy model. Prev Med 2001, 33: 558–570. 10.1006/pmed.2001.0922PubMedCrossRef
6.
go back to reference Orme ME, Hogue SL, Kennedy LM, Paine AC, Godfrey C: Development of the health and economic consequences of smoking interactive model. Tob Control 2001, 10: 55–61. 10.1136/tc.10.1.55PubMedCentralPubMedCrossRef Orme ME, Hogue SL, Kennedy LM, Paine AC, Godfrey C: Development of the health and economic consequences of smoking interactive model. Tob Control 2001, 10: 55–61. 10.1136/tc.10.1.55PubMedCentralPubMedCrossRef
7.
go back to reference Johansson PM, Tillgren PE, Guldbrandsson KA, Lindholm LA: A model for cost-effectiveness analyses of smoking cessation interventions applied to a Quit-and-Win contest for mothers of small children. Scand J Public Health 2005, 33: 343–352. 10.1080/14034940510005789PubMedCrossRef Johansson PM, Tillgren PE, Guldbrandsson KA, Lindholm LA: A model for cost-effectiveness analyses of smoking cessation interventions applied to a Quit-and-Win contest for mothers of small children. Scand J Public Health 2005, 33: 343–352. 10.1080/14034940510005789PubMedCrossRef
8.
go back to reference Guidelines for the Pharmaceutical Industry on preparation of submissions to the Pharmaceutical Benefits Advisory Committee. Canberra, Commonwealth Department of Health and Ageing; 2002. Guidelines for the Pharmaceutical Industry on preparation of submissions to the Pharmaceutical Benefits Advisory Committee. Canberra, Commonwealth Department of Health and Ageing; 2002.
9.
go back to reference Mathers C, Vos T, Stevenson C: The burden of disease and injury in Australia. AIHW cat. no. PHE 17. Canberra, Australian Institute of Health and Welfare; 1999. Mathers C, Vos T, Stevenson C: The burden of disease and injury in Australia. AIHW cat. no. PHE 17. Canberra, Australian Institute of Health and Welfare; 1999.
10.
go back to reference Hunink M, Glasziou P, Siegel J, Weeks J, Pliskin J, Elstein A, Weinstein M: Decision making in health and medicine. Integrating evidence and values.. Cambridge, Cambridge University Press; 2001. Hunink M, Glasziou P, Siegel J, Weeks J, Pliskin J, Elstein A, Weinstein M: Decision making in health and medicine. Integrating evidence and values.. Cambridge, Cambridge University Press; 2001.
11.
go back to reference TreeAge Pro 2006 User's Manual. Williamstown, MA, TreeAge Software Inc; 2006. TreeAge Pro 2006 User's Manual. Williamstown, MA, TreeAge Software Inc; 2006.
12.
go back to reference Briggs A, Sculpher M: An introduction to Markov modelling for economic evaluation. Pharmacoeconomics 1998, 13: 397–409. 10.2165/00019053-199813040-00003PubMedCrossRef Briggs A, Sculpher M: An introduction to Markov modelling for economic evaluation. Pharmacoeconomics 1998, 13: 397–409. 10.2165/00019053-199813040-00003PubMedCrossRef
13.
go back to reference GRIM (General Record of Incidence of Mortality) Books. Canberra, Australian Institute of Health and Welfare; 2005. GRIM (General Record of Incidence of Mortality) Books. Canberra, Australian Institute of Health and Welfare; 2005.
14.
go back to reference Jamrozik K, Dobson A, Hobbs M, McElduff P, Ring I, D'Este K, Crome M: Monitoring the incidence of cardiovascular disease in Australia. Cardiovascular Disease Series Number 17 edition. Canberra, Australian Institute of Health and Welfare; 2001. Jamrozik K, Dobson A, Hobbs M, McElduff P, Ring I, D'Este K, Crome M: Monitoring the incidence of cardiovascular disease in Australia. Cardiovascular Disease Series Number 17 edition. Canberra, Australian Institute of Health and Welfare; 2001.
15.
go back to reference McElduff P, Dobson A, Jamrozik K, Hobbs M: The WHO MONICA Study, Australia, 1984–93. A summary of the Newcastle and Perth MONICA Projects. Cardiovascular Disease Series Number 13 edition. Canberra, Australian Institute of Health and Welfare; 2000. McElduff P, Dobson A, Jamrozik K, Hobbs M: The WHO MONICA Study, Australia, 1984–93. A summary of the Newcastle and Perth MONICA Projects. Cardiovascular Disease Series Number 13 edition. Canberra, Australian Institute of Health and Welfare; 2000.
17.
go back to reference Thrift AG, Dewey HM, Macdonell RAL, McNeil JJ, Donnan GA: Stroke Incidence on the East Coast of Australia. The North East Melbourne Stroke Incidence Study (NEMESIS). Stroke 2000, 31: 2087–2092.PubMedCrossRef Thrift AG, Dewey HM, Macdonell RAL, McNeil JJ, Donnan GA: Stroke Incidence on the East Coast of Australia. The North East Melbourne Stroke Incidence Study (NEMESIS). Stroke 2000, 31: 2087–2092.PubMedCrossRef
18.
go back to reference Dewey HM, Thrift AG, Mihalopoulos C, Carter R, Macdonell RA, McNeil JJ, Donnan GA: 'Out of pocket' costs to stroke patients during the first year after stroke - results from the North East Melbourne Stroke Incidence Study. J Clin Neurosci 2004, 11: 134–137. 10.1016/S0967-5868(03)00148-6PubMedCrossRef Dewey HM, Thrift AG, Mihalopoulos C, Carter R, Macdonell RA, McNeil JJ, Donnan GA: 'Out of pocket' costs to stroke patients during the first year after stroke - results from the North East Melbourne Stroke Incidence Study. J Clin Neurosci 2004, 11: 134–137. 10.1016/S0967-5868(03)00148-6PubMedCrossRef
20.
go back to reference Barendregt JJ, Van Oortmarssen GJ, Vos T, Murray CJ: A generic model for the assessment of disease epidemiology: the computational basis of DisMod II. Population Health Metrics 2003, 1: 4. 10.1186/1478-7954-1-4PubMedCentralPubMedCrossRef Barendregt JJ, Van Oortmarssen GJ, Vos T, Murray CJ: A generic model for the assessment of disease epidemiology: the computational basis of DisMod II. Population Health Metrics 2003, 1: 4. 10.1186/1478-7954-1-4PubMedCentralPubMedCrossRef
21.
go back to reference 4364.0 National Health Survey - Summary of Results, Australia. Canberra, Australian Bureau of Statistics; 2002. 4364.0 National Health Survey - Summary of Results, Australia. Canberra, Australian Bureau of Statistics; 2002.
23.
go back to reference English DR, Holman CD, Milne E, al. : The quantification of drug caused morbidity and mortality in Australia 1995. Canberra, Department of Human Services and Health; 1995. English DR, Holman CD, Milne E, al. : The quantification of drug caused morbidity and mortality in Australia 1995. Canberra, Department of Human Services and Health; 1995.
24.
go back to reference Peto R, Lopez AD, Boreham J, Thun M, Heath C: Mortality from tobacco in developed countries: indirect estimation from national vital statistics. Lancet 2005, 339: 1268–1278. 10.1016/0140-6736(92)91600-DCrossRef Peto R, Lopez AD, Boreham J, Thun M, Heath C: Mortality from tobacco in developed countries: indirect estimation from national vital statistics. Lancet 2005, 339: 1268–1278. 10.1016/0140-6736(92)91600-DCrossRef
25.
go back to reference Lightwood JM, Glantz SA: Short-term economic and health benefits of smoking cessation. Circulation 1997, 96: 1089–1096.PubMedCrossRef Lightwood JM, Glantz SA: Short-term economic and health benefits of smoking cessation. Circulation 1997, 96: 1089–1096.PubMedCrossRef
26.
go back to reference Peto R, Darby S, Deo H, Silcocks P, Whitley E, Doll R: Smoking, smoking cessation, and lung cancer in the UK since 1950: combination of national statistics with two case-control studies. BMJ 2000, 321: 323–329. 10.1136/bmj.321.7257.323PubMedCentralPubMedCrossRef Peto R, Darby S, Deo H, Silcocks P, Whitley E, Doll R: Smoking, smoking cessation, and lung cancer in the UK since 1950: combination of national statistics with two case-control studies. BMJ 2000, 321: 323–329. 10.1136/bmj.321.7257.323PubMedCentralPubMedCrossRef
27.
go back to reference Hardie K, Jamrozik K, Hankey G, Broadhurst RJ, Anderson C: Trends in five-year survival and risk of recurrent stroke after first-ever stroke in the Perth Community Stroke Study. Cerebrovascular Diseases 2005, 19: 179–185. 10.1159/000083253PubMedCrossRef Hardie K, Jamrozik K, Hankey G, Broadhurst RJ, Anderson C: Trends in five-year survival and risk of recurrent stroke after first-ever stroke in the Perth Community Stroke Study. Cerebrovascular Diseases 2005, 19: 179–185. 10.1159/000083253PubMedCrossRef
28.
go back to reference Hardie K, Hankey GJ, Jamrozik K, Broadhurst RJ, Anderson C: Ten-year survival after first-ever stroke in the Perth Community stroke study. Stroke 2003, 34: 1842–1846. 10.1161/01.STR.0000082382.42061.EEPubMedCrossRef Hardie K, Hankey GJ, Jamrozik K, Broadhurst RJ, Anderson C: Ten-year survival after first-ever stroke in the Perth Community stroke study. Stroke 2003, 34: 1842–1846. 10.1161/01.STR.0000082382.42061.EEPubMedCrossRef
29.
go back to reference Taylor DH, Hasselbad V, Henley J, Thun MJ, Sloan FA: Benefits of Smoking Cessation for Longevity. American Journal of Public Health 2002, 92: 990–996.PubMedCentralPubMedCrossRef Taylor DH, Hasselbad V, Henley J, Thun MJ, Sloan FA: Benefits of Smoking Cessation for Longevity. American Journal of Public Health 2002, 92: 990–996.PubMedCentralPubMedCrossRef
30.
go back to reference Mathur S: Epidemic of coronary heart disease and its treatment in Australia. Cardiovascular disease series Number 20.. Canberra, Australian Institute of Health and Welfare; 2002. Mathur S: Epidemic of coronary heart disease and its treatment in Australia. Cardiovascular disease series Number 20.. Canberra, Australian Institute of Health and Welfare; 2002.
32.
go back to reference Dewey H, Thrift AG, Mihalopoulos C, Carter R, Macdonell RAL, McNeil JJ, Donnan GA: Lifetime cost of stroke subtypes in Australia. Findings from the North East Melbourne Stroke Incidence Study (NEMESIS). Stroke 2003, 34: 2502–2507. 10.1161/01.STR.0000091395.85357.09PubMedCrossRef Dewey H, Thrift AG, Mihalopoulos C, Carter R, Macdonell RAL, McNeil JJ, Donnan GA: Lifetime cost of stroke subtypes in Australia. Findings from the North East Melbourne Stroke Incidence Study (NEMESIS). Stroke 2003, 34: 2502–2507. 10.1161/01.STR.0000091395.85357.09PubMedCrossRef
33.
go back to reference Rosenthal M, Webster PJ, Gebski VJ, Stuart-Harris RC, Langlands AO, Boyages J: The cost of treating small cell lung cancer. Medical Journal of Australia 1992, 156: 605–610.PubMed Rosenthal M, Webster PJ, Gebski VJ, Stuart-Harris RC, Langlands AO, Boyages J: The cost of treating small cell lung cancer. Medical Journal of Australia 1992, 156: 605–610.PubMed
34.
go back to reference Oliver E, Killen J, Kiebert G, Hutton J, Hall R, Higgins B, Bourke S, Paschen B: Treatment pathways, resource use and costs in the management of small cell lung cancer. Thorax 2001, 56: 785–790. 10.1136/thorax.56.10.785PubMedCentralPubMedCrossRef Oliver E, Killen J, Kiebert G, Hutton J, Hall R, Higgins B, Bourke S, Paschen B: Treatment pathways, resource use and costs in the management of small cell lung cancer. Thorax 2001, 56: 785–790. 10.1136/thorax.56.10.785PubMedCentralPubMedCrossRef
35.
go back to reference Chapman KR, Bourbeau J, Rance L: The burden of COPD in Canada: results from the Confronting COPD. Respiratory Medicine 2003, 97: S23-S31. 10.1016/S0954-6111(03)80022-7PubMedCrossRef Chapman KR, Bourbeau J, Rance L: The burden of COPD in Canada: results from the Confronting COPD. Respiratory Medicine 2003, 97: S23-S31. 10.1016/S0954-6111(03)80022-7PubMedCrossRef
38.
go back to reference Tengs TO, Lin TH: A meta-analysis of quality-of-life estimates for stroke. Pharmacoeconomics 2003, 21: 191–200. 10.2165/00019053-200321030-00004PubMedCrossRef Tengs TO, Lin TH: A meta-analysis of quality-of-life estimates for stroke. Pharmacoeconomics 2003, 21: 191–200. 10.2165/00019053-200321030-00004PubMedCrossRef
39.
go back to reference Sturm JW, Donnan GA, Dewey HM, Macdonell RA, Gilligan AK, Srikanth V, Thrift AG: Quality of life after stroke: the North East Melbourne Stroke Incidence Study (NEMESIS). Stroke 2004, 35: 2340–2345. 10.1161/01.STR.0000141977.18520.3bPubMedCrossRef Sturm JW, Donnan GA, Dewey HM, Macdonell RA, Gilligan AK, Srikanth V, Thrift AG: Quality of life after stroke: the North East Melbourne Stroke Incidence Study (NEMESIS). Stroke 2004, 35: 2340–2345. 10.1161/01.STR.0000141977.18520.3bPubMedCrossRef
40.
go back to reference Trippoli S, Vaiani M, Lucioni C, Messori A: Quality of life and utility in patients with non-small cell lung cancer. Quality-of-life Study Group of the Master 2 Project in Pharmacoeconomics. Pharmacoeconomics 2001, 19: 855–863. 10.2165/00019053-200119080-00007PubMedCrossRef Trippoli S, Vaiani M, Lucioni C, Messori A: Quality of life and utility in patients with non-small cell lung cancer. Quality-of-life Study Group of the Master 2 Project in Pharmacoeconomics. Pharmacoeconomics 2001, 19: 855–863. 10.2165/00019053-200119080-00007PubMedCrossRef
41.
go back to reference Ko CY, Maggard M, Livingston EH: Evaluating health utility in patients with melanoma, breast cancer, colon cancer, and lung cancer: a nationwide, population-based assessment. J Surg Res 2003, 114: 1–5. 10.1016/S0022-4804(03)00167-7PubMedCrossRef Ko CY, Maggard M, Livingston EH: Evaluating health utility in patients with melanoma, breast cancer, colon cancer, and lung cancer: a nationwide, population-based assessment. J Surg Res 2003, 114: 1–5. 10.1016/S0022-4804(03)00167-7PubMedCrossRef
42.
go back to reference The health consequences of smoking: a report of the Surgeon General. Atlanta,GA, U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health.; 2004. The health consequences of smoking: a report of the Surgeon General. Atlanta,GA, U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health.; 2004.
43.
go back to reference He J, Vupputuri S, Allen K, Prerost MR, Hughes J, Whelton PK: Passive smoking and the risk of coronary heart disease--a meta-analysis of epidemiologic studies. N Engl J Med 1999, 340: 920–926. 10.1056/NEJM199903253401204PubMedCrossRef He J, Vupputuri S, Allen K, Prerost MR, Hughes J, Whelton PK: Passive smoking and the risk of coronary heart disease--a meta-analysis of epidemiologic studies. N Engl J Med 1999, 340: 920–926. 10.1056/NEJM199903253401204PubMedCrossRef
44.
go back to reference Sargent RP, Shepard RM, Glantz SA: Reduced incidence of admissions for myocardial infarction associated with public smoking ban: before and after study. British Medical Journal 2004, 328: 977–983. 10.1136/bmj.38055.715683.55PubMedCentralPubMedCrossRef Sargent RP, Shepard RM, Glantz SA: Reduced incidence of admissions for myocardial infarction associated with public smoking ban: before and after study. British Medical Journal 2004, 328: 977–983. 10.1136/bmj.38055.715683.55PubMedCentralPubMedCrossRef
45.
go back to reference Lightwood JM, Phibbs CS, Glantz SA: Short-term health and economic benefits of smoking cessation: low birth weight. Pediatrics 1999, 104: 1312–1320. 10.1542/peds.104.6.1312PubMedCrossRef Lightwood JM, Phibbs CS, Glantz SA: Short-term health and economic benefits of smoking cessation: low birth weight. Pediatrics 1999, 104: 1312–1320. 10.1542/peds.104.6.1312PubMedCrossRef
46.
go back to reference McElduff P, Dobson A, Beaglehole R, Jackson R: Rapid reduction in coronary risk for those who quit cigarette smoking. Australian and New Zealand Journal of Health 1998, 22: 787–791.CrossRef McElduff P, Dobson A, Beaglehole R, Jackson R: Rapid reduction in coronary risk for those who quit cigarette smoking. Australian and New Zealand Journal of Health 1998, 22: 787–791.CrossRef
47.
go back to reference Rosenberg L, Palmer JR, Shapiro S: Decline in the risk of myocardial infarction among women who stop smoking. New England Journal of Medicine 1990, 322: 213–217.PubMedCrossRef Rosenberg L, Palmer JR, Shapiro S: Decline in the risk of myocardial infarction among women who stop smoking. New England Journal of Medicine 1990, 322: 213–217.PubMedCrossRef
48.
go back to reference Rosenberg L, Kaufman DW, Helmrich SP, Shapiro S: The risk of myocardial infarction after quitting smoking in men under 55 years of age. New England Journal of Medicine 1985, 313: 1511–1514.PubMedCrossRef Rosenberg L, Kaufman DW, Helmrich SP, Shapiro S: The risk of myocardial infarction after quitting smoking in men under 55 years of age. New England Journal of Medicine 1985, 313: 1511–1514.PubMedCrossRef
49.
go back to reference Willett WC, Hennekens CH, Bain C, Rosner B, Speizer FE: Cigarette smoking and non-fatal myocardial infarction in women. American Journal of Epidemiology 1981, 113: 575–582.PubMed Willett WC, Hennekens CH, Bain C, Rosner B, Speizer FE: Cigarette smoking and non-fatal myocardial infarction in women. American Journal of Epidemiology 1981, 113: 575–582.PubMed
50.
go back to reference Kawachi I, Colditz G, Stampfer MJ, Willett WC, Manson JE, Rosner B, Speizer FE, Hennekens CH: Smoking cessation and time course of decreased risks of coronary heart disease in middle-aged women. Archives of Internal Medicine 1994, 154: 169–175. 10.1001/archinte.154.2.169PubMedCrossRef Kawachi I, Colditz G, Stampfer MJ, Willett WC, Manson JE, Rosner B, Speizer FE, Hennekens CH: Smoking cessation and time course of decreased risks of coronary heart disease in middle-aged women. Archives of Internal Medicine 1994, 154: 169–175. 10.1001/archinte.154.2.169PubMedCrossRef
51.
go back to reference Kawachi I, Colditz G, Stampfer MJ, Willet WC, Manson JE, Rosner B, Speizer FE, Hennekens CH: Smoking cessation and decreased risk of stroke in women. JAMA 1993, 269: 232–236. 10.1001/jama.269.2.232PubMedCrossRef Kawachi I, Colditz G, Stampfer MJ, Willet WC, Manson JE, Rosner B, Speizer FE, Hennekens CH: Smoking cessation and decreased risk of stroke in women. JAMA 1993, 269: 232–236. 10.1001/jama.269.2.232PubMedCrossRef
52.
go back to reference Wannamethee SG, Shaper G, Whincup PH, Walker M: Smoking cessation and the risk of stroke in middle-aged men. JAMA 1995, 274: 155–160. 10.1001/jama.274.2.155PubMedCrossRef Wannamethee SG, Shaper G, Whincup PH, Walker M: Smoking cessation and the risk of stroke in middle-aged men. JAMA 1995, 274: 155–160. 10.1001/jama.274.2.155PubMedCrossRef
Metadata
Title
The Quit Benefits Model: a Markov model for assessing the health benefits and health care cost savings of quitting smoking
Authors
Susan F Hurley
Jane P Matthews
Publication date
01-12-2007
Publisher
BioMed Central
Published in
Cost Effectiveness and Resource Allocation / Issue 1/2007
Electronic ISSN: 1478-7547
DOI
https://doi.org/10.1186/1478-7547-5-2

Other articles of this Issue 1/2007

Cost Effectiveness and Resource Allocation 1/2007 Go to the issue